Multidisciplinary Management of Esophageal Cancer

JCO Oncol Pract. 2026 Jun 3:OP2600198. doi: 10.1200/OP-26-00198. Online ahead of print.ABSTRACTEsophageal cancer (EC) is a highly lethal malignancy with geographic, histologic, and biologic heterogeneity. Advances in endoscopic therapy, multimodality treatment, biomarker-driven systemic therapy, and

A Anas M Barabrah

Fluorescence-lifetime optical electrophysiology in contracting cardiomyocytes

Proc Natl Acad Sci U S A. 2026 Jun 9;123(23):e2533881123. doi: 10.1073/pnas.2533881123. Epub 2026 Jun 3.ABSTRACTPrecise monitoring of cardiac electrophysiology in vitro is crucial to understanding heart function and cardiac disease. However, high-throughput, contact-free methods for directly measuri

E Euan Millar

Safety of low lipoprotein(a) levels: the FOURIER trial

Eur Heart J. 2026 Jun 3:ehag398. doi: 10.1093/eurheartj/ehag398. Online ahead of print.ABSTRACTBACKGROUND AND AIMS: Lipoprotein(a) (Lp(a)) is considered a causal risk factor for atherogenesis. A higher prevalence of certain adverse events, including diabetes mellitus (DM), has been reported for pati

B Baris Gencer

Exercise mimetics: molecular mechanisms, biological and therapeutic effects

Mol Biomed. 2026 Jun 3;7(1):81. doi: 10.1186/s43556-026-00483-8.ABSTRACTAccumulating evidence underscores the therapeutic benefits of exercise in the prevention and treatment of various diseases. However, many patients are unable to engage in sufficient physical training because of frailty, disabili

J Jienan Zhang

Old and New Lines of Therapy Targeting Lipoprotein(a)

Curr Atheroscler Rep. 2026 Jun 3;28(1):59. doi: 10.1007/s11883-026-01419-x.ABSTRACTPURPOSE OF REVIEW: Elevated lipoprotein(a) (Lp[a]) is a prevalent, lifelong, and genetically determined causal cardiovascular risk factor, associated with a wide spectrum of cardiovascular disease, including atheroscl

K Khalil Anchouche